The association analysis between CP2c and nuclear YY1 expression in breast tumor tissues showed that patients with YY1-high and CP2c-low expression showed the most favorable survival outcomes (Figure 4), whereas those with high CP2c expression had a bad prognosis regardless of the nuclear YY1 expression level, suggesting that CP2c is a driver of breast cancer progression. Here, YY1 is linked to breast cancer.